India's Richest People 2026 edition · 1 director · Source: Hurun India
- #326 Sujit Jaysukh Bhayani & family ₹11,600 Cr
Market Cap
₹10,974 Cr
SUDEEPPHRM · NSE
Share Price
₹962.00
-0.99% today
Revenue
₹642 Cr
FY 2025-26 · +27.9% YoY
EBITDA
₹223 Cr
Margin 34.7%
Net Profit
₹173 Cr
FY 2025-26 · +24.3% YoY
P/E (TTM)
62.1x
P/B 12.8x
ROE
25.4%
ROCE 27.9%
Debt / Equity
0.21
Interest cover 4.1x
About Sudeep Pharma Limited
Data last updated:
Sudeep Pharma Limited is a public limited company based in Vadodara, Gujarat, India. It operates in the preventive health supplements segment of the healthcare sector. It was incorporated on 21 December 1989 and has been in existence for over 37 years.
Its director Sujit Jaysukh Bhayani and family are #326 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24231GJ1989PLC013141. Its GSTIN is 24AACCS9716J1Z4 (Gujarat). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 544619 and NSE: SUDEEPPHRM.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹11.29 Cr. It is led by directors including Sujit Jaysukh Bhayani (Managing Director) and Shanil Sujit Bhayani (Whole-Time Director).
Its last annual general meeting (AGM) was held on 04 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 129/1/A G.I.D.C. Estate Nandesari, Vadodara, Gujarat, India – 391340.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹642.26 Cr, a growth of 27.9% compared to the previous year. For the same year it recorded a net profit of ₹172.92 Cr (net margin 26.9%) and EBITDA of ₹222.8 Cr (EBITDA margin 34.7%). The net worth stands at ₹883.33 Cr (up 79.1% YoY). Total assets are valued at ₹1,078.31 Cr (up 70.5% YoY).
The company has about 377 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Sudeep Pharma and Sudeep Pharma. As per MCA filings, the company has open charges of ₹271.5 Cr and satisfied charges of ₹81.9 Cr on record. Court records list 21 cases involving the company, including 6 filed by the company and 15 filed against it. The company has 11 deals on record (6 secondary share transfers, 2 funding rounds, 2 market trades), with disclosed funding of ₹170 Cr; the latest was in November 2025. The company has 4 MSME Form 1 returns on record between 2019 and 2021, listing 424 overdue payments to 124 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sudeepgroup.com.
Company details
CIN L24231GJ1989PLC013141
Registration Number 013141
Incorporation Date 21 December 1989
ROC Ahmedabad
Listing Status Listed - Listed on NSE (SUDEEPPHRM); Listed on BSE (544619)
Company Status Active
Date of Last AGM 04 August 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
CIN history
Sudeep Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24231GJ1989PLC013141, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231GJ1989PLC013141 | Current |
| U24231GJ1989PLC013141 | Previous |
| U24231GJ1989PTC013141 | Previous |
Key People
Sujit Jaysukh Bhayani Managing Director Shanil Sujit Bhayani Whole-Time Director Ajay Shrirang Kandelkar Whole-Time Director Recognitions & Rankings of Sudeep Pharma
Contact details
Sudeep Pharma Limited's registered office is in Baroda, Gujarat.
- Registered Address129/1/A G.I.D.C. Estate Nandesari, Vadodara, Gujarat, India – 391340
- IndustryHealthcare, Preventive Health Supplements
Comprehensive company report
Sudeep Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Sudeep Pharma operates two associated brands: Sudeep Pharma and Sudeep Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical excipients and ingredients are manufactured for multiple industries. | sudeeppharma.com | |
| Sudeep Pharma is involved in pharmaceutical and nutrition sectors. | sudeepgroup.com |
Business activity
The main business activity of Sudeep Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Sudeep Pharma Limited, buy the company report.
Financials of Sudeep Pharma Limited
FY 2025-26 filings availableSudeep Pharma Limited reported revenue of ₹642.26 Cr (up 27.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹642 Cr
+27.9% YoY
EBITDA
₹223 Cr
+16.6% YoY
Profit After Tax
₹173 Cr
+24.3% YoY
Net Worth
₹883 Cr
+79.1% YoY
Total Assets
₹1,078 Cr
+70.5% YoY
Total Debt
₹150 Cr
+9.4% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 642 | 502 | 459 | 429 | 343 | 215 | 123 |
| Revenue growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| EBITDA | 223 | 191 | 182 | 90.16 | 67.47 | 44.08 | 25.38 |
| EBITDA margin | +34.7% | +38.1% | +39.7% | +21.0% | +19.7% | +20.5% | +20.6% |
| Profit before tax | 228 | 183 | 175 | 85.98 | 68.61 | 43.02 | 24.60 |
| Net profit | 173 | 139 | 133 | 62.38 | 50.08 | 33.27 | 18.04 |
| Net profit margin | +26.9% | +27.7% | +29.1% | +14.6% | +14.6% | +15.5% | +14.7% |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Balance sheet | |||||||
| Total assets | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Net worth | 883 | 493 | 356 | 223 | 163 | 114 | 80.95 |
| Total debt | 150 | 138 | 78.08 | 83.09 | 83.69 | 31.06 | 20.17 |
| Cash & bank | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Net working capital | 537 | 346 | 203 | 119 | 105 | 36.67 | 32.04 |
| Cash flow | |||||||
| Cash from operations | 69.55 | 48.73 | 65.69 | 48.40 | (2.98) | 35.28 | 9.87 |
| Cash from investing | (327) | (78.59) | (49.28) | (49.79) | (38.42) | (40.42) | (22.47) |
| Cash from financing | 247 | 52.70 | (12.74) | (9.78) | 50.92 | 13.00 | 12.45 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 158 | 182 | 172 | 163 | 125 | 158 | 116 | 149 |
| Revenue growth (YoY) | +26.7% | +15.7% | +49.2% | +9.3% | +55.9% | - | - | - |
| Other income | 5.45 | 6.42 | 6.84 | 10.17 | 5.16 | 3.76 | 2.44 | 1.87 |
| EBITDA | 54.91 | 62.60 | 59.98 | 55.47 | 43.88 | 58.78 | 39.30 | 63.47 |
| EBITDA margin | +34.7% | +34.3% | +34.8% | +34.1% | +35.1% | +37.3% | +34.0% | +42.7% |
| Depreciation | 4.00 | 3.88 | 3.86 | 3.81 | 3.25 | 2.83 | 2.67 | 2.58 |
| Interest | 2.06 | 2.44 | 1.17 | 2.28 | 1.71 | 1.85 | 1.41 | 1.05 |
| Profit before tax | 54.30 | 62.70 | 61.79 | 59.55 | 44.08 | 57.86 | 37.66 | 61.71 |
| Tax | 13.71 | 14.15 | 14.08 | 12.76 | 12.80 | 13.67 | 8.94 | 12.97 |
| Net profit | 40.59 | 48.55 | 47.71 | 46.79 | 31.28 | 44.19 | 28.72 | 48.74 |
| EPS (₹) | 3.59 | 4.38 | 4.29 | 4.20 | 2.84 | 4.07 | 2.65 | 4.49 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 339 | 357 | 344 | 404 | 345 | 218 |
| Revenue growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| EBITDA | 120 | 133 | 133 | 89.25 | 68.14 | 45.79 |
| EBITDA margin | +35.6% | +37.2% | +38.7% | +22.1% | +19.8% | +21.0% |
| Profit before tax | 145 | 129 | 132 | 90.77 | 70.40 | 44.96 |
| Net profit | 107 | 95.60 | 97.99 | 67.17 | 52.01 | 34.92 |
| Net profit margin | +31.7% | +26.8% | +28.5% | +16.6% | +15.1% | +16.0% |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Balance sheet | ||||||
| Total assets | 913 | 552 | 396 | 308 | 242 | 148 |
| Net worth | 786 | 430 | 335 | 237 | 168 | 116 |
| Total debt | 127 | 120 | 60.48 | 70.52 | 72.66 | 31.06 |
| Cash & bank | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Net working capital | 404 | 265 | 180 | 128 | 105 | 34.37 |
| Cash flow | ||||||
| Cash from operations | 96.02 | 59.15 | 59.05 | 42.31 | (5.33) | 35.81 |
| Cash from investing | (367) | (91.59) | (40.67) | (40.71) | (27.97) | (44.71) |
| Cash from financing | 242 | 54.20 | (16.14) | (10.11) | 39.98 | 13.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 106 | 80.17 | 90.28 | 87.88 | 80.17 | 105 | 83.48 | 106 |
| Revenue growth (YoY) | +31.8% | -23.5% | +8.2% | -17.3% | +29.1% | - | - | - |
| Other income | 9.80 | 9.62 | 9.44 | 12.83 | 6.62 | 3.10 | 2.29 | 1.44 |
| Total expenses | 66.49 | 51.28 | 60.67 | 57.00 | 49.78 | 59.39 | 57.02 | 66.10 |
| EBITDA | 39.19 | 28.89 | 29.61 | 30.88 | 30.39 | 45.46 | 26.46 | 40.20 |
| EBITDA margin | +37.1% | +36.0% | +32.8% | +35.1% | +37.9% | +43.4% | +31.7% | +37.8% |
| Depreciation | 1.83 | 1.79 | 1.79 | 1.77 | 1.75 | 1.71 | 1.53 | 1.47 |
| Interest | 1.76 | 1.97 | 0.63 | 2.03 | 1.44 | 1.58 | 1.25 | 0.71 |
| Profit before tax | 45.40 | 34.75 | 36.63 | 39.91 | 33.82 | 45.27 | 25.97 | 39.46 |
| Tax | 11.58 | 8.98 | 9.76 | 10.17 | 8.63 | 12.15 | 5.34 | 10.02 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 158 | 182 | 172 | 163 | 125 | 158 | 116 | 149 |
| Revenue growth (YoY) | +26.7% | +15.7% | +49.2% | +9.3% | +55.9% | - | - | - |
| Other income | 5.45 | 6.42 | 6.84 | 10.17 | 5.16 | 3.76 | 2.44 | 1.87 |
| EBITDA | 54.91 | 62.60 | 59.98 | 55.47 | 43.88 | 58.78 | 39.30 | 63.47 |
| EBITDA margin | +34.7% | +34.3% | +34.8% | +34.1% | +35.1% | +37.3% | +34.0% | +42.7% |
| Depreciation | 4.00 | 3.88 | 3.86 | 3.81 | 3.25 | 2.83 | 2.67 | 2.58 |
| Interest | 2.06 | 2.44 | 1.17 | 2.28 | 1.71 | 1.85 | 1.41 | 1.05 |
| Profit before tax | 54.30 | 62.70 | 61.79 | 59.55 | 44.08 | 57.86 | 37.66 | 61.71 |
| Tax | 13.71 | 14.15 | 14.08 | 12.76 | 12.80 | 13.67 | 8.94 | 12.97 |
| Net profit | 40.59 | 48.55 | 47.71 | 46.79 | 31.28 | 44.19 | 28.72 | 48.74 |
| EPS (₹) | 3.59 | 4.38 | 4.29 | 4.20 | 2.84 | 4.07 | 2.65 | 4.49 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 642 | 502 | 459 | 429 | 343 | 215 | 123 |
| Revenue growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| Other income | 28.59 | 9.33 | 6.10 | 9.52 | 7.39 | 3.44 | 3.22 |
| Total expenses | 419 | 311 | 277 | 339 | 276 | 171 | 97.63 |
| Employee cost | 51.89 | 38.34 | 29.41 | 66.10 | 15.55 | 11.46 | 9.34 |
| EBITDA | 223 | 191 | 182 | 90.16 | 67.47 | 44.08 | 25.38 |
| EBITDA margin | +34.7% | +38.1% | +39.7% | +21.0% | +19.7% | +20.5% | +20.6% |
| Depreciation | 14.81 | 10.59 | 9.01 | 7.92 | 4.53 | 3.53 | 3.07 |
| Interest | 8.50 | 6.90 | 4.74 | 5.78 | 1.72 | 0.97 | 0.93 |
| Profit before tax | 228 | 183 | 175 | 85.98 | 68.61 | 43.02 | 24.60 |
| Tax | 53.79 | 44.12 | 41.63 | 23.66 | 18.43 | 9.68 | 6.56 |
| Net profit | 173 | 139 | 133 | 62.38 | 50.08 | 33.27 | 18.04 |
| Net profit margin | +26.9% | +27.7% | +29.1% | +14.6% | +14.6% | +15.5% | +14.7% |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 11.29 | 11.98 | 1.41 | 1.41 | 1.41 | 1.41 | 1.41 |
| Reserves & surplus | 872 | 481 | 355 | 222 | 162 | 113 | 79.54 |
| Shareholders' funds (net worth) | 883 | 493 | 356 | 223 | 163 | 114 | 80.95 |
| Minority interest | 14.75 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 148 | 135 | 75.03 | 82.26 | 83.69 | 31.06 | 17.09 |
| Unsecured loans | 2.13 | 2.30 | 3.05 | 0.83 | 0.00 | 0.00 | 3.08 |
| Total debt | 150 | 138 | 78.08 | 83.09 | 83.69 | 31.06 | 20.17 |
| Total liabilities | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Assets | |||||||
| Gross block | 378 | 216 | 197 | 166 | 157 | 83.31 | 71.80 |
| Net block | 337 | 189 | 180 | 158 | 137 | 67.65 | 59.58 |
| Capital work in progress | 185 | 88.22 | 44.66 | 25.97 | 8.13 | 24.00 | 8.16 |
| Investments | 0.00 | 0.14 | 0.13 | 3.03 | 0.00 | 19.10 | 6.00 |
| Inventories | 216 | 129 | 66.58 | 71.00 | 36.54 | 17.47 | 9.50 |
| Sundry debtors | 228 | 185 | 145 | 93.71 | 107 | 55.18 | 30.32 |
| Cash & bank balances | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Loans & advances | 65.73 | 58.15 | 50.11 | 51.98 | 31.68 | 14.89 | 12.39 |
| Total current assets | 624 | 424 | 275 | 227 | 197 | 99.50 | 56.31 |
| Total current liabilities | 87.17 | 78.41 | 72.58 | 108 | 91.53 | 62.83 | 24.27 |
| Net working capital | 537 | 346 | 203 | 119 | 105 | 36.67 | 32.04 |
| Total assets | 1,078 | 632 | 435 | 307 | 248 | 146 | 102 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 36.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 | 4.25 |
| Net cash from operating activities | 69.55 | 48.73 | 65.69 | 48.40 | (2.98) | 35.28 | 9.87 |
| Net cash from investing activities | (327) | (78.59) | (49.28) | (49.79) | (38.42) | (40.42) | (22.47) |
| Net cash from financing activities | 247 | 52.70 | (12.74) | (9.78) | 50.92 | 13.00 | 12.45 |
| Net change in cash | (10.07) | 22.83 | 3.67 | (11.17) | 9.52 | 7.86 | (0.16) |
| Closing cash | 115 | 51.81 | 13.98 | 10.30 | 21.47 | 11.96 | 4.10 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +27.9% | +9.3% | +7.1% | +25.0% | +59.5% | +74.9% | - |
| EBITDA growth | +16.6% | +4.7% | +102.4% | +33.6% | +53.1% | +73.7% | - |
| PBT growth | +24.7% | +4.6% | +103.3% | +25.3% | +59.5% | +74.9% | +9997.0% |
| Net income growth | +24.3% | +4.3% | +113.9% | +24.6% | +50.5% | +84.4% | - |
| Revenue CAGR (3Y) | +14.4% | +13.5% | +28.8% | +51.6% | - | - | - |
| EBITDA CAGR (3Y) | +35.2% | +41.5% | +60.6% | +52.6% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +27.1% | +27.6% | +29.0% | +14.5% | +14.6% | +15.5% | +14.7% |
| Return on capital employed | +27.9% | +35.5% | +48.4% | +33.1% | +35.7% | +35.4% | +25.0% |
| Return on net worth | +25.4% | +32.8% | +46.0% | +32.2% | +36.2% | +34.2% | +22.3% |
| Debt / equity | 0.21 | 0.25 | 0.28 | 0.43 | 0.41 | 0.26 | 0.25 |
| Long-term debt / equity | 0.06 | 0.06 | 0.06 | 0.13 | 0.15 | 0.11 | 0.10 |
| Interest cover | 4.09 | 3.82 | 2.73 | 7.03 | 2.73 | 2.39 | 4.17 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.16 | 2.43 | 2.53 | 2.65 | 2.86 | 2.77 | 1.71 |
| Inventory turnover | 3.73 | 5.14 | 6.68 | 7.97 | 12.70 | 15.95 | 12.95 |
| Debtors turnover | 3.11 | 3.04 | 3.85 | 4.27 | 4.23 | 5.03 | 4.06 |
| EPS (₹) | 15.31 | 14.27 | 94.53 | 44.23 | 356.01 | 236.61 | 128.02 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 78.21 | 50.48 | 252.69 | 158.47 | 1,159.15 | 810.48 | 574.46 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 106 | 80.17 | 90.28 | 87.88 | 80.17 | 105 | 83.48 | 106 |
| Revenue growth (YoY) | +31.8% | -23.5% | +8.2% | -17.3% | +29.1% | - | - | - |
| Other income | 9.80 | 9.62 | 9.44 | 12.83 | 6.62 | 3.10 | 2.29 | 1.44 |
| Total expenses | 66.49 | 51.28 | 60.67 | 57.00 | 49.78 | 59.39 | 57.02 | 66.10 |
| EBITDA | 39.19 | 28.89 | 29.61 | 30.88 | 30.39 | 45.46 | 26.46 | 40.20 |
| EBITDA margin | +37.1% | +36.0% | +32.8% | +35.1% | +37.9% | +43.4% | +31.7% | +37.8% |
| Depreciation | 1.83 | 1.79 | 1.79 | 1.77 | 1.75 | 1.71 | 1.53 | 1.47 |
| Interest | 1.76 | 1.97 | 0.63 | 2.03 | 1.44 | 1.58 | 1.25 | 0.71 |
| Profit before tax | 45.40 | 34.75 | 36.63 | 39.91 | 33.82 | 45.27 | 25.97 | 39.46 |
| Tax | 11.58 | 8.98 | 9.76 | 10.17 | 8.63 | 12.15 | 5.34 | 10.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Revenue | 339 | 357 | 344 | 404 | 345 | 218 |
| Revenue growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| Other income | 38.50 | 8.38 | 8.20 | 11.18 | 8.08 | 3.67 |
| Total expenses | 218 | 224 | 211 | 315 | 277 | 172 |
| Employee cost | 28.95 | 26.06 | 20.22 | 60.79 | 13.55 | 11.46 |
| EBITDA | 120 | 133 | 133 | 89.25 | 68.14 | 45.79 |
| EBITDA margin | +35.6% | +37.2% | +38.7% | +22.1% | +19.8% | +21.0% |
| Depreciation | 7.11 | 6.12 | 5.15 | 4.83 | 4.19 | 3.53 |
| Interest | 6.73 | 5.68 | 3.68 | 4.83 | 1.63 | 0.97 |
| Profit before tax | 145 | 129 | 132 | 90.77 | 70.40 | 44.96 |
| Tax | 37.51 | 33.66 | 34.23 | 23.60 | 18.10 | 9.97 |
| Net profit | 107 | 95.60 | 97.99 | 67.17 | 52.01 | 34.92 |
| Net profit margin | +31.7% | +26.8% | +28.5% | +16.6% | +15.1% | +16.0% |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 11.29 | 11.98 | 1.41 | 1.41 | 1.41 | 1.41 |
| Reserves & surplus | 775 | 418 | 333 | 235 | 167 | 115 |
| Shareholders' funds (net worth) | 786 | 430 | 335 | 237 | 168 | 116 |
| Secured loans | 125 | 119 | 58.05 | 69.69 | 72.66 | 31.06 |
| Unsecured loans | 1.72 | 1.78 | 2.43 | 0.83 | 0.00 | 0.00 |
| Total debt | 127 | 120 | 60.48 | 70.52 | 72.66 | 31.06 |
| Total liabilities | 913 | 552 | 396 | 308 | 242 | 148 |
| Assets | ||||||
| Gross block | 124 | 120 | 106 | 94.64 | 139 | 83.31 |
| Net block | 102 | 105 | 95.89 | 89.82 | 120 | 67.65 |
| Capital work in progress | 161 | 87.71 | 43.50 | 25.59 | 4.38 | 23.21 |
| Investments | 32.07 | 31.51 | 28.75 | 18.70 | 15.11 | 24.21 |
| Inventories | 131 | 64.60 | 45.42 | 52.40 | 26.33 | 15.10 |
| Sundry debtors | 80.13 | 162 | 141 | 126 | 123 | 58.14 |
| Cash & bank balances | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Loans & advances | 157 | 40.70 | 35.40 | 47.81 | 27.71 | 14.86 |
| Total current assets | 458 | 313 | 231 | 233 | 192 | 96.29 |
| Total current liabilities | 53.75 | 48.20 | 50.96 | 105 | 86.61 | 61.92 |
| Net working capital | 404 | 265 | 180 | 128 | 105 | 34.37 |
| Total assets | 913 | 552 | 396 | 308 | 242 | 148 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Opening cash | 30.35 | 8.59 | 6.35 | 14.87 | 8.19 | 4.10 |
| Net cash from operating activities | 96.02 | 59.15 | 59.05 | 42.31 | (5.33) | 35.81 |
| Net cash from investing activities | (367) | (91.59) | (40.67) | (40.71) | (27.97) | (44.71) |
| Net cash from financing activities | 242 | 54.20 | (16.14) | (10.11) | 39.98 | 13.00 |
| Net change in cash | (28.16) | 21.75 | 2.24 | (8.52) | 6.68 | 4.09 |
| Closing cash | 90.09 | 45.35 | 8.59 | 6.35 | 14.87 | 8.19 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | -5.1% | +3.8% | -14.9% | +17.1% | +58.3% | - |
| EBITDA growth | -9.3% | -0.1% | +48.9% | +31.0% | +48.8% | - |
| PBT growth | +12.1% | -2.2% | +45.7% | +28.9% | +56.6% | +9997.0% |
| Net income growth | +12.4% | -2.4% | +45.9% | +29.2% | +48.9% | - |
| Revenue CAGR (3Y) | -5.7% | +1.1% | +16.4% | - | - | - |
| EBITDA CAGR (3Y) | +10.5% | +24.9% | +42.7% | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | +31.8% | +26.8% | +28.5% | +16.6% | +15.2% | +16.1% |
| Return on capital employed | +20.7% | +28.5% | +38.7% | +34.8% | +37.0% | +36.7% |
| Return on net worth | +17.7% | +25.1% | +34.3% | +33.2% | +36.8% | +35.5% |
| Debt / equity | 0.20 | 0.24 | 0.23 | 0.35 | 0.36 | 0.26 |
| Long-term debt / equity | 0.06 | 0.06 | 0.03 | 0.07 | 0.11 | 0.11 |
| Interest cover | 5.94 | 4.48 | 2.88 | 5.72 | 2.55 | 2.30 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 2.77 | 3.16 | 3.43 | 3.46 | 3.11 | 2.81 |
| Inventory turnover | 3.47 | 6.48 | 7.03 | 10.26 | 16.65 | 17.71 |
| Debtors turnover | 2.79 | 2.35 | 2.57 | 3.24 | 3.81 | 4.93 |
| EPS (₹) | 9.52 | 9.85 | 696.04 | 476.69 | 371.20 | 248.29 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 69.59 | 44.01 | 2,374.56 | 1,681.07 | 1,193.96 | 822.76 |
To see the full year-wise statements and ratios of Sudeep Pharma Limited, buy the company report.
Board of directors of Sudeep Pharma Limited
Sudeep Pharma has 8 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
Showing 6 of 8 current directors. View all directors
Charges & borrowings
Open charges
₹271.5 Cr
Satisfied charges
₹81.9 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 13 Jul 2026 | 101352762 | The Hongkong and Shanghai Banking Corporation Limited | ₹125 Cr | Open | |
| 30 Dec 2024 | 101026268 | Others | ₹75 Cr | Open | |
| 29 Sep 2020 | 100376016 | Citi Bank N.A. | ₹20 Cr | Open | |
| 20 Aug 2019 | 100289600 | Citi Bank N.A. | ₹6.5 Cr | Open | |
| 27 Jan 2014 | 10475518 | Citi Bank N.A. | ₹45 Cr | Open |
To see the full charge records of Sudeep Pharma Limited, buy the company report.
Total charge records: 18 View all charges
Deals & funding
Sudeep Pharma Limited has 11 deals on record (6 secondary share transfers, 2 funding rounds, 2 market trades), with disclosed funding of ₹170 Cr; the latest was in November 2025.
Total deals
11
Secondary share transfers
6
Funding rounds
2
Market trades
2
IPO
1
Disclosed funding
₹170 Cr
Deals on record (5 of 11)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Nov 2025 | Market trade | ₹447.7 Cr | Buyer: Junomoneta Finsol Private Limited , Goldmine Stocks Pvt Ltd, Irage Broking Services LLP Seller: Junomoneta Finsol Private Limited , Irage Broking Services LLP , Goldmine Stocks Pvt Ltd |
| Nov 2025 | Market trade | ₹64.11 Cr | Buyer: Irage Broking Services LLP Seller: Irage Broking Services LLP |
| Nov 2025 | IPO | ₹895 Cr | Investors: Sbi Life Insurance Company Limited , Shamyak Investment Private Limited , Tata Aia Life Insurance Company Limited Seller: Sujeet Jaysukh Bhayani HUF, 3 individuals |
| May 2025 | Funding round | ₹160 Cr | Investors: Ashok India Equity Investment Trust Plc, Whiteoak Capital Opportunities Fund, Dalmia Family Office Trust |
| Jan 2018 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
To see the full deal history of Sudeep Pharma Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Sudeep Pharma Limited has 21 court cases on record: 6 filed by Sudeep Pharma, 15 filed against it. All cases are disposed.
Total cases
21
Filed by the company
6
Filed against the company
15
Disposed
21
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 15 | 12 | 0 |
| High courts | 5 | 3 | 0 |
| NCLT | 1 | 0 | 0 |
Cases on record (5 of 21)
| Court | Type of case | Party | Status |
|---|---|---|---|
| NCLT, Mumbai | Insolvency matter | Filed by the company against Celogen Pharma Private Limited | Disposed |
| High Court, GUJARAT | Court case (COMP) | Filed against the company by Penta Freight Pvt. Ltd | Disposed |
| District court, Vadodara, Gujarat | Criminal complaint | Filed against the company by Government of Gujarat | Disposed |
| District court, Vadodara, Gujarat | Criminal complaint | Filed against the company by Income - Tax Department Through Its Officer Navin Sinha | Disposed |
| District court, Vadodara, Gujarat | Civil suit | Filed against the company by individuals | Disposed |
To see the full case history of Sudeep Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Sudeep Pharma Limited has 4 MSME Form 1 returns on record between 2019 and 2021, listing 424 overdue payments to 124 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 124)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Saita Screens & Filters | |||
| an individual supplier | |||
| Thermolab Scientific Equipments Private Limited | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Sudeep Pharma Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Sudeep Pharma has 2 GST registrations: 2 active.
Total GSTINs
2
Active
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AACCS9716J1Z4 | Gujarat | Active | 01 Jul 2017 |
| 03AACCS9716J1Z8 | Punjab | Active | 09 Jan 2024 |
To see the full GST registrations and return filing status of Sudeep Pharma Limited, buy the company report.
Recent activity
Sudeep Pharma Limited has 25 board changes on record since 1995: 9 appointments and 16 cessations. The latest: Milin Kaimas Mehta was appointed as Director on 26 Jun 2026.
AGM
Sudeep Pharma Limited last Annual general meeting of members was held on 04 Aug 2026 as per latest MCA records.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 125.00 Cr with Charge ID 101352762 was registered on 13 Jul 2026.
Appointed
Milin Kaimas Mehta was appointed as Director.
Filing
Sudeep Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge with Others of Rs. 75.00 Cr registered on 30 Dec 2024 with Charge ID 101026268 was modified on 17 Sep 2025.
Charges
A charge with Others amounted to Rs. 75.00 Cr with Charge ID 101026268 was registered on 30 Dec 2024.
Charges
A charge registered on 29 Jan 2022 via Charge ID 100539717 with Others was fully satisfied on 12 Dec 2024.
Ceased
Raghunandan Sathyanarayan Rao ceased to be Additional Director.
Ceased
Reshma Suresh Patel ceased to be Additional Director.
Ceased
Samaresh Parida ceased to be Additional Director.
Ceased
Sujit Gulati ceased to be Additional Director.
Appointed
Ajay Shrirang Kandelkar was appointed as Whole-Time Director.
56 earlier events are in the company report.
News
Frequently asked questions
Sudeep Pharma is an active public limited company based in Vadodara, Gujarat, India. The company works in preventive health supplements, within the healthcare industry. It was incorporated on 21 December 1989 (37+ years old) and is registered under CIN L24231GJ1989PLC013141. Listed on BSE: 544619 and NSE: SUDEEPPHRM.
Sudeep Pharma reported revenue of ₹642.26 Cr for FY 2025-26 (up 27.9% YoY) based on consolidated financials.
Sudeep Pharma has 8 current directors:
- Sujit Jaysukh Bhayani - Managing Director
- Shanil Sujit Bhayani - Whole-Time Director
- Ajay Shrirang Kandelkar - Whole-Time Director
- Samaresh Parida - Director
- Raghunandan Sathyanarayan Rao - Director
- Sujit Gulati - Director
- Reshma Suresh Patel - Director
- Milin Kaimas Mehta - Director
The latest financial statements of Sudeep Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 04 August 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Sudeep Pharma is 24AACCS9716J1Z4, registered in Gujarat. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 03AACCS9716J1Z8 (Punjab).
The CIN (Corporate Identification Number) of Sudeep Pharma is L24231GJ1989PLC013141. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Sudeep Pharma is a listed company as per MCA records. Its shares are listed on both BSE (code: 544619) and NSE (symbol: SUDEEPPHRM).
Sudeep Pharma has 21 court cases on record: 6 filed by the company and 15 filed against it. Most are in the district courts.
Sudeep Pharma was incorporated on 21 December 1989, making it 37+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Sudeep Pharma has 11 deals on record (6 secondary share transfers, 2 funding rounds, 2 market trades), with disclosed funding of ₹170 Cr; the latest was in November 2025.
Milin Kaimas Mehta was appointed as Director on 26 Jun 2026. Raghunandan Sathyanarayan Rao ceased to be Additional Director on 25 Oct 2024. Reshma Suresh Patel ceased to be Additional Director on 25 Oct 2024. Sudeep Pharma has 25 board changes on record in total.